^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    Viral entry inhibitor

    Related drugs:
    2d
    A Pharmaco-surgical Approach to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery (clinicaltrials.gov)
    P=N/A, N=242, Completed, Massachusetts General Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Mar 2025
    Trial completion • Trial completion date
    3d
    PATRONUS: Pragmatic Amiodarone Trial to Reduce Postoperative Atrial Fibrillation in Patients Undergoing Cardiac Surgery (clinicaltrials.gov)
    P4, N=242, Not yet recruiting, Massachusetts General Hospital | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Jul 2025 --> Jan 2027
    Trial completion date • Trial primary completion date
    11d
    A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection (clinicaltrials.gov)
    P1/2, N=33, Completed, Vir Biotechnology, Inc. | Active, not recruiting --> Completed | N=150 --> 33 | Trial completion date: Mar 2027 --> Aug 2025
    Trial completion • Enrollment change • Trial completion date
    17d
    Shortening Duration of Antiarrhythmic Medication for SVT in Infants (clinicaltrials.gov)
    P=N/A, N=107, Completed, Tampere University Hospital | Recruiting --> Completed | N=70 --> 107
    Trial completion • Enrollment change
    18d
    RESTART: Reducing Systemic Inflammation in People on Antiretroviral Therapy (clinicaltrials.gov)
    P2, N=150, Recruiting, Centre hospitalier de l'Université de Montréal (CHUM) | Not yet recruiting --> Recruiting
    Enrollment open
    23d
    A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection (clinicaltrials.gov)
    P3, N=124, Active, not recruiting, Vir Biotechnology, Inc. | Recruiting --> Active, not recruiting
    Enrollment closed
    25d
    A Study to Evaluate the Safety and Antiviral Activity of Two Human Monoclonal Antibodies (VRC07-523LS and PGT121.414.LS) During Analytic Treatment Interruption in Participants Living With HIV Who Initiated ART During Acute/Early HIV-1 Infection (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, National Institute of Allergy and Infectious Diseases (NIAID) | Initiation date: Oct 2025 --> Feb 2026
    Trial initiation date
    25d
    An Extension Protocol for Subjects Who Successfully Completed PRO140_CD02 or PRO140_CD02_Open Label Study (clinicaltrials.gov)
    P2/3, N=43, Terminated, CytoDyn, Inc. | Active, not recruiting --> Terminated; FDA required the sponsor to halt enrollment in the trial and transition participants to available therapies for the treatment of their disease. The trial was subsequently terminated once participants were transitioned.
    Trial termination
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4)
    |
    Vyrologix (leronlimab)
    25d
    Proteome-wide mendelian randomization identifies FCRL3 and LY9 as potential therapeutic targets for lymphoma. (PubMed, Discov Oncol)
    Our study identified 37 potential lymphoma drug targets, emphasizing FCRL3 and LY9 as valuable therapeutic candidates, and amiodarone and chrysin in clinical translational application.
    Journal
    |
    LY9 (Lymphocyte Antigen 9) • LY75 (Lymphocyte Antigen 75) • APOBEC3G (Apolipoprotein B MRNA Editing Enzyme Catalytic Subunit 3G) • MAPK3 (Mitogen-Activated Protein Kinase 3)
    1m
    PRO 140_CD03 Extension: An Extension Protocol for Virologically Suppressed Subjects Who Successfully Completed PRO140_CD03 Study (clinicaltrials.gov)
    P2/3, N=56, Terminated, CytoDyn, Inc. | Active, not recruiting --> Terminated; FDA required the sponsor to halt enrollment in the trial and transition participants to available therapies for the treatment of their disease. The trial was subsequently terminated once participants were transitioned.
    Trial termination
    |
    Vyrologix (leronlimab)
    2ms
    MARCH: Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection (clinicaltrials.gov)
    P2, N=244, Active, not recruiting, Vir Biotechnology, Inc. | Trial completion date: Jun 2027 --> Mar 2026 | Trial primary completion date: Jun 2027 --> Mar 2026
    Trial completion date • Trial primary completion date
    2ms
    VISTA: HIV-1 Virologic Suppression With TMB-365 and TMB-380 Antibodies Study (clinicaltrials.gov)
    P2, N=75, Not yet recruiting, TaiMed Biologics Inc.
    New P2 trial